Pharmacotherapeutic management of osteoprosis and osteopenia.
Alexander
Ivy M
IM
Yale University School of Nursing, Yale University Health Services, New Haven, CT, USA.
D000465:Algorithms; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D016903:Drug Monitoring; D015914:Estrogen Replacement Therapy; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008403:Mass Screening; D009722:Nurse Practitioners / Q000458:organization & administration; D009730:Nursing Assessment; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000379:methods*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D019379:Teriparatide / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D019379:Teriparatide; D020849:Raloxifene Hydrochloride; D002116:Calcitonin